Skip to main content
. 2021 Feb 25;2:647134. doi: 10.3389/falgy.2021.647134

Figure 6.

Figure 6

P4rr decreased β-glucosyl ceramides in plasma, lung and liver of allergic mothers. (A) Mothers were sensitized and challenged with OVA or saline and then mated. Mothers received daily subcutaneous (s.c.) injections of (B) P4rr or the inactive (S,S) stereoisomer. P4rr or P4ss were administered during pregnancy (GD5-GD20) and during nursing (PND3-13) to allergic mothers. At postnatal day 3 (PND3), pups in all groups received one intraperitoneal (i.p) sensitization with OVA/alum. At PND10-12, pups in all groups received 3 challenges with OVA. For experiments with maternal and fetal analysis, tissues were collected on GD18. For experiments with pup analysis, tissues were collected on PND13. Tissue β-glucosyl ceramides (C–E) and β-galactosyl ceramides (Supplementary Figure 9) were separated by column chromatography and then analyzed by mass spectrometry. (C) Mom plasma. (D) Mom lung. (E) Mom liver. n = 8–10 mice per group for a representative experiment of two experiments. *p < 0.05 compared to NT, OVA allergic mother, crimson red highlighted chain lengths are above the panels.